Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin for primary prevention of heart attack gains AHA support, more data needed.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN FOR HEART ATTACK PRIMARY PREVENTION "MAY BE WARRANTED" in at-risk individuals, the American Heart Association recommends in a scientific statement published in the Oct. 21 issue of the journal Circulation. AHA notes, however, that any policy recommendation on primary prevention of cardiovascular disease would be "premature" until more evidence from random primary prevention trials is collected. Entitled "Aspirin as a Therapeutic Agent in Cardiovascular Disease," the statement directed at health care professionals was prepared by Charles Hennekens, MD, Brigham & Women's Hospital, Boston, et al.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel